82 related articles for article (PubMed ID: 17716321)
1. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF
Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
[TBL] [Abstract][Full Text] [Related]
3. Beneficial Effects of Kiatsu™ with Ki Training on Episodic Migraine: An Exploratory Study.
Tabata CY; Copenhaver PF; McCartney S; Vazinkhoo S; Copperman T
Pain Res Manag; 2021; 2021():3290879. PubMed ID: 34745397
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
6. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
Pellesi L; Do TP; Ashina H; Ashina M; Burstein R
Headache; 2020 Jun; 60(6):1056-1065. PubMed ID: 32437038
[TBL] [Abstract][Full Text] [Related]
7. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache.
Sargent J; Solbach P; Damasio H; Baumel B; Corbett J; Eisner L; Jessen B; Kudrow L; Mathew N; Medina J
Headache; 1985 Sep; 25(6):320-4. PubMed ID: 3902723
[No Abstract] [Full Text] [Related]
8. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
9. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.
Pijpers JA; Kies DA; Louter MA; van Zwet EW; Ferrari MD; Terwindt GM
Brain; 2019 May; 142(5):1203-1214. PubMed ID: 30982843
[TBL] [Abstract][Full Text] [Related]
10. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
Bruloy E; Sinna R; Grolleau JL; Bout-Roumazeilles A; Berard E; Chaput B
Plast Reconstr Surg; 2019 Jan; 143(1):239-250. PubMed ID: 30589800
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
Petri S; Tölle T; Straube A; Pfaffenrath V; Stefenelli U; Ceballos-Baumann A;
Eur Neurol; 2009; 62(4):204-11. PubMed ID: 19622887
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A in refractory chronic migraine: an open-label trial.
Menezes C; Rodrigues B; Magalhães E; Melo A
Arq Neuropsiquiatr; 2007 Sep; 65(3A):596-8. PubMed ID: 17876397
[TBL] [Abstract][Full Text] [Related]
13. Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines.
Dima L; Bălan A; Moga MA; Dinu CG; Dimienescu OG; Varga I; Neculau AE
Toxins (Basel); 2019 Aug; 11(8):. PubMed ID: 31398813
[TBL] [Abstract][Full Text] [Related]
14. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.
Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives NJ; Clarke CE; Sinclair AJ
BMJ Open; 2019 Jul; 9(7):e027953. PubMed ID: 31315864
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxins for the prevention of migraine in adults.
Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
[TBL] [Abstract][Full Text] [Related]
16. Botulinum Toxin in Migraine Treatment.
Ilgaz Aydinlar E; Yalinay Dikmen P; Sağduyu Kocaman A
Noro Psikiyatr Ars; 2013 Aug; 50(Suppl 1):S36-S40. PubMed ID: 28360582
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic use of botulinum toxin in migraine: mechanisms of action.
Ramachandran R; Yaksh TL
Br J Pharmacol; 2014 Sep; 171(18):4177-92. PubMed ID: 24819339
[TBL] [Abstract][Full Text] [Related]
18. Chronic migraine--classification, characteristics and treatment.
Diener HC; Dodick DW; Goadsby PJ; Lipton RB; Olesen J; Silberstein SD
Nat Rev Neurol; 2012 Feb; 8(3):162-71. PubMed ID: 22331030
[TBL] [Abstract][Full Text] [Related]
19. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.
Robertson CE; Garza I
Neuropsychiatr Dis Treat; 2012; 8():35-48. PubMed ID: 22275844
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic migraine.
Diener HC; Holle D; Dodick D
Curr Pain Headache Rep; 2011 Feb; 15(1):64-9. PubMed ID: 21080112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
